Unfortunately, going to the hospital today and being diagnosed with Covid-19 often guarantees a one way trip to EUA treatment, isolation, ventilation and death. Dr. Fauci's NIH protocols often include an elixir of lung sedatives such as Midazolam (used in legal injections), experimental Remdesivir (which is known to damage kidneys) and the Ventilator.

If you are hospitalized and don't have an AD (Advanced Directive) already pre-loaded in your medical chart, or are asked to sign a "consent for treatment" form, have that consent form printed out, **DO NOT SIGN the general electronic version**. On the printed version, you can customize its contents, crossing out and adding declarations as needed such as those noted above (NO VENTILATORS, NO REMDESIVIR, etc.) Then sign and date the updated form and return to the hospital.

Some Relevant Remdesivir Studies:

Rapid review of suspected adverse drug events due to Remdesivir in the WHO database; findings and implications https://pubmed.ncbi.nlm.nih.gov/33252992/

Conclusions: Deterioration of liver and kidney function are frequently observed ADEs (Adverse Drug Events) with Remdesivir; consequently, patients should be monitored for these ADEs.

Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database https://pubmed.ncbi.nlm.nih.gov/33340409/

"...we detected a statistically significant pharmacovigilance signal of nephrotoxicity associated with Remdesivir, deserving a thorough qualitative assessment of all available data."

Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. https://journals.asm.org/doi/epdf/10.1128/AAC.01117-21

"Here, we critically evaluate the assumptions of the models underlying Remdesivir's promising preclinical data and show that such assumptions over-predict efficacy and minimize toxicity of Remdesivir in humans."

Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283561/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283561/</a>

"In this cohort study of 2344 US veterans hospitalized with COVID-19, Remdesivir therapy was not associated with improved 30-day survival but was associated with a significant increase in median time to hospital discharge.

The findings suggest that routine use of Remdesivir may be associated with increased use of hospital beds but not with improvements in survival."

#### Remdesivir of scant benefit in hospitalized COVID patients, study finds

https://www.cidrap.umn.edu/news-perspective/2020/08/remdesivir-scant-benefit-hospitalized-covid-patients-study-finds
"The antiviral drug Remdesivir had little effect in patients with moderate COVID-19 in 105 hospitals in the United States, Europe, and
Asia in a randomized, controlled, open-label trial published late last week in JAMA, adding to a mixed picture of the drug in randomized clinical trials (RCTs), which are considered the gold standard for gauging interventions."

### Medical Advocacy 101:

Once hospitalized, it is vital that your Medical Freedom Army activate and start doing everything in their power to get you out of the hospital. Once a safe transfer and care can be guaranteed, the patient should arrange discharge from the hospital. Depending on the patient's status, an Against Medical Advice form may need to be completed in order to relieve the hospital of any liability. Each hospital will likely offer particular services to patients and it is every patient's right to be made aware of these advocacy services such as social workers, ethics committees and hospital designated patient advocates. The following attachment provides a helpful guide for navigating and communicating with the hospital and the patient's associated care team.

# Medical Advocacy

Examples of Treatments to Advocate for are Listed Below.

\*\*\*Copies of these protocols should be given your hospital providers AND all relevant parties and committees associated with the patient's care (i.e., hospital ethics committees, protocol committees, patient advocates, social workers, etc.)

Make sure that these boards and committees are also being held accountable for neglecting these well-founded, safe and effective treatments.

### FLCCC Hospital Treatment Protocol (MATH+):

https://covid19criticalcare.com/covid-19-protocols/math-plus-protocol/



FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19

# MATH+ HOSPITAL TREATMENT PROTOCOL FOR COVID-19

Page 1/2

Version 13 2021-06-30

METHYLPREDNISOLONE  A. Upon oxygen requirement or abnormal chest X-ray  Preferred: 80 mg IV bolus, then 40 mg IV twice daily Alternate: 80 mg / 240 ml normal saline IV infusion at 10 ml/hr Follow COVID-19 Respiratory Failure protocol (see flccc.net/respiratory-support-c19/)  B. Refractory Illness/Cytokine Storm  "Pulse" dose with 125 – 250 mg IV every 6 hours  Preferred: 80 mg IV bolus, then 40 mg IV twice daily Alternate: 80 mg / 240 ml normal saline IV infusion at 10 ml/hr Follow COVID-19 Respiratory Failure protocol (see flccc.net/respiratory-support-c19/)  B. Refractory Illness/Cytokine Storm  "Pulse" dose with 125 – 250 mg IV Continue × 3 days then decrease to 160 mg/day × 5 days then 10 mg/day × 5 days then 10 mg/day × 5 days then 10 mg/day × 5 days then decrease to 160 mg/daily dose above, taper according to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording to oxyge requirement (A). If no response or CRP/Fe high/rising, on sid	MEDICATION	INDICATION/INITIATION	RECOMMENDED DOSING	TITRATION/DURATION	
Alternate: 80 mg / 240 ml normal saline IV infusion at 10 ml/hr Follow COVID-19 Respiratory Failure protocol (see flccc.net/respiratory-support-c19/)  B. Refractory Illness/ Cytokine Storm  Pulse "Dos Mays x 5 days then 10 mg/day x 5 days then 10 mg/day x 5 days then 10 mg/day x 6 days x 5 days then 10 mg/day x 6 days x 5 days then 10 mg/day x 6 days x 5 days then 10 mg/day x 6 days x 5 days then 10 mg/day x 6 days x 5 days then 10 mg/day x 6 days x 5 days then 10 mg/day x 6 days x 5 days then 10 mg/day x 6 days x 6 days x 6 days then 10 mg/day x 6 days x		A. Upon oxygen require-	Preferred: 80 mg IV bolus, then 40 mg IV	A1. If no improvement in oxygenation in 2–4 days	
Protocol (see flocc.net/respiratory-support-c19/)			Alternate: 80 mg/240 ml normal saline IV	A2. Upon need for FIO <sub>2</sub> > 0.6 or ICU, escalate to	
Cytokine Storm   every 6 hours   daily dose above, taper according to oxystequirement (A). If no response or CRP/Fe high/rising, consider mega-dose IV ascording of the proving   O2 < 4L on hospital ward   500-1000 mg oral every 6 hours   Until discharge			protocol	A3. Once off IMV, NPPV, or High flow $O_2$ , decrease t 20 mg twice daily. Once off $O_2$ , then taper wit 20 mg/day $\times$ 5 days then 10 mg/day $\times$ 5 days	
Proceedings   Processes   Pr				Continue × 3 days then decrease to 160 mg IV/ daily dose above, taper according to oxygen requirement (A). If no response or CRP/Ferritin high/rising, consider mega-dose IV ascorbic acid and/or "Therapeutic Plasma Exchange" below	
Switch to oral dose above   Switch to oral dose above   If in ICU and not improving   Consider mega-doses: 25 grams IV twice daily for 3 days   Completion of 3 days of therapy	ASCORBIC ACID	O <sub>2</sub> < 4 L on hospital ward	500-1000 mg oral every 6 hours	Until discharge	
THIAMINE  ICU patients  200 mg IV twice daily or 3 days  THIAMINE  ICU patients  200 mg IV twice daily  If initiated on a hospital ward  If initiated in the ICU  Initiated in the ICU  Initiated in the ICU  Initiated in the ICU  Initiatiated Initiated in the ICU  Initiatiated Initiated Initiated in the ICU  Initiatiated Initiated Initi		O <sub>2</sub> >4L or in ICU	50 mg/kg IV every 6 hours	Up to 7 days or until discharge from ICU, then switch to oral dose above	
HEPARIN (LMWH)  If initiated on a hospital ward  If initiated in the ICU  IVERMECTIN*		,		Completion of 3 days of therapy	
hospital ward   Monitor anti-Xa levels, target 0.6–1.1 IU/ml   If initiated in the ICU   0.5 mg/kg twice daily — Monitor anti-Xa levels, target 0.2–0.5 IU/ml   VERMECTIN* (a core medication)   Upon admission to hospital and/or ICU   0.4–0.6 mg/kg per dose — daily (Take with or after meals)   For 5 days or until recovered   If any of: 1) on fluvoxamine, 2) hypoxemic, 3) tachy-pneic/respiratory distress, 4) oliguric/kidney injury   Oliguric/kidney injury   Until discharge, slow taper once sustaine improvements noted   Until fully recovered   Until fully recovered   Until discharge	THIAMINE	ICU patients	200 mg IV twice daily	Up to 7 days or until discharge from ICU	
Initiated in the ICU	HEPARIN (LMWH)			Until discharge then start DOAC at half dose × 4 weeks	
(a core medication) to hospital and/or ICU (Take with or after meals)  Fluvoxamine ** Hospitalized patients 50 mg PO twice daily 10–14 days  Cyproheptadine If any of: 1) on fluvoxamine, 2) hypoxemic, 3) tachypneic/respiratory distress, 4) oliguric/kidney injury  Anti-Androgen Therapy Hospitalized patients (Men only) Dutasteride 0.5 mg daily or Finasteride 5 mg daily  Vitamin D Hospitalized patients Calcifediol preferred: 0.5 mg PO day 1, then 0.2 mg PO day 2 and weekly thereafter Cholecalciferol: 20,000–60,000 IU single dose PO then 20,000 IU weekly  Atorvastatin ICU Patients 80 mg PO daily Until discharge		If initiated in the ICU			
Cyproheptadine  If any of: 1) on fluvoxamine, 2) hypoxemic, 3) tachypneic/respiratory distress, 4) oliguric/kidney injury  Anti-Androgen Therapy  Hospitalized patients (Men only)  Vitamin D  Hospitalized patients Calcifediol preferred: 0.5 mg PO day 1, then 0.2 mg PO day 2 and weekly thereafter Cholecalciferol: 20,000–60,000 IU single dose PO then 20,000 IU weekly  Atorvastatin  ICU Patients  Remg — 3 x daily until discharge, slow taper once sustaine improvements noted improvements noted improvements noted until discharge, slow taper once sustaine improvements noted improvements noted improvements noted until discharge, slow taper once sustaine improvements noted improvements noted until discharge, slow taper once sustaine improvements noted improvements noted until discharge, slow taper once sustaine improvements noted improvements noted until discharge, slow taper once sustaine improvements noted until discharge, slow taper once sus			0.4–0.6 mg/kg per dose — daily (Take with or after meals)	For 5 days or until recovered	
2) hypoxemic, 3) tachy- pneic/respiratory distress, 4) oliguric/kidney injury  Anti-Androgen Therapy Hospitalized patients (Men only)  Vitamin D Hospitalized patients Calcifediol preferred: 0.5 mg PO day 1, then 0.2 mg PO day 2 and weekly thereafter Cholecalciferol: 20,000–60,000 IU single dose PO then 20,000 IU weekly  Atorvastatin  ICU Patients  Bo mg PO daily  improvements noted  until fully recovered Until discharge Until discharge Until discharge	Fluvoxamine **	Hospitalized patients	50 mg PO twice daily	10-14 days	
Vitamin D  Hospitalized patients Calcifediol preferred: 0.5 mg PO day 1, then 0.2 mg PO day 2 and weekly thereafter Cholecalciferol: 20,000–60,000 IU single dose PO then 20,000 IU weekly  Atorvastatin  ICU Patients 80 mg PO daily Until discharge Until discharge	Cyproheptadine	<ol><li>hypoxemic, 3) tachy- pneic/respiratory distress,</li></ol>	- ,	until discharge, slow taper once sustained improvements noted	
0.2 mg PO day 2 and weekly thereafter Cholecalciferol: 20,000–60,000 IU single dose PO then 20,000 IU weekly  Atorvastatin ICU Patients 80 mg PO daily Until discharge	Anti-Androgen Therapy			until fully recovered	
dose PO then 20,000 IU weekly  Atorvastatin ICU Patients 80 mg PO daily Until discharge	Vitamin D	Hospitalized patients		Until discharge	
	Atorvastatin	ICU Patients	80 mg PO daily	Until discharge	

Melatonin	Hospitalized patients	6–12 mg PO at night	Until discharge
Zinc	Hospitalized patients	75-100 mg PO daily	Until discharge
Famotidine	Hospitalized Patients	40-80 mg PO twice daily	Until discharge
Therapeutic Plasma Exchange	Patients refractory to pulse dose steroids	5 sessions, every other day	Completion of 5 exchanges

Legend: CRP = C-Reactive Protein, DOAC = direct oral anti-coagulant, FIO<sub>2</sub> = Fraction of inspired oxygen, ICU = Intensive Care Unit, IMV = Invasive Mechanical Ventilation, IU = International units, IV = Intravenous, NIPPV = Non-Invasive Positive Pressure Ventilation, O<sub>2</sub> = oxygen, PO (per os) = oral administration

- \* The safety of Ivermectin in pregnancy has not been established thus treatment decisions require an assessment of the risks vs. benefits in a given clinical situation.
- \*\* Some individuals who are prescribed fluvoxamine experience acute anxiety which needs to be carefully monitored for and treated by the prescribing clinician to prevent rare escalation to suicidal or violent behavior.

For optional medicines and an overview of the developments in prevention and treatment of COVID-19, please visit flccc.net/optional-medicines



Please check our homepage www.flccc.net regularly for updates of our COVID-19 Protocols! – New medications may be added and/or dose changes to existing medications may be made as further scientific studies emerge!

flccc.net



FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19

Page 2/2

Version 13 2021-06-30

## MATH+ HOSPITAL TREATMENT PROTOCOL FOR COVID-19

### TO CONTROL INFLAMMATION & EXCESS CLOTTING

In all COVID-19 hospitalized patients, the therapeutic focus must be placed on early intervention utilizing powerful, evidencebased therapies to counteract:

- The overwhelming and damaging inflammatory response
- The systemic and severe hyper-coagulable state causing organ damage

By initiating the protocol <u>soon after a patient meets criteria for oxygen supplementation</u>, the need for mechanical ventilators and ICU beds will decrease dramatically.

#### TREATMENT OF LOW OXYGEN

- If patient has low oxygen saturation on nasal cannula, initiate heated high flow nasal cannula.
- Do not hesitate to increase flow limits as needed.
- Avoid early intubation that is based solely on oxygen requirements. Allow "permissive hypoxemia" as tolerated.
- Intubate only if patient demonstrates excessive work of breathing.
- Utilize "prone positioning" to help improve oxygen saturation.

#### ABOUT THE MATH+ HOSPITAL TREATMENT PROTOCOL FOR COVID-19

Our MATH+ protocol is designed for hospitalized patients, to counter the body's overwhelming inflammatory response to the SARS-CoV-2 virus. The protocol is based on numerous medical journal publications over decades. It is the hyper-inflammation, not the virus itself, that damages the lungs and other organs and ultimately causes death in COVID-19. We have found the MATH+ protocol to be a highly effective combination therapy in controlling this extreme inflammatory response and we have now added ivermectin as a core component given the profound emerging efficacy data in hospitalized patients reviewed here (www.flccc.net/flccc-ivermectin-review-covid-19).

The steroid Methylprednisolone is a key component, increasing numbers of studies (see https://flccc.net/medical-evidence) show its profound effectiveness in COVID-19, which is made more potent when administered intravenously with high

anticoagulant Heparin is important for preventing and dissolving blood clots that appear with a very high frequency in patients not given blood thinners. The + sign indicates several important co-interventions that have strong physiologic rationale and an excellent safety profile. It also indicates that we plan to adapt the protocol as our insights and the published medical evidence evolve.

Timing is a critical factor in the successful treatment of COVID-19. Patients must go to the hospital as soon as they experience difficulty breathing or have a low oxygen level. The MATH+ protocol then should be administered soon after a patient meets criteria for oxygen supplementation (within the first hours after arrival in the hospital), in order to achieve maximal efficacy as delayed therapy has led to complications such as the need for mechanical ventilation.

Te 1 . . . 1 1 d. e 1 ePDA 1 e

doses of the antioxidant Ascorbic acid given that the two medicines have multiple synergistic physiologic effects. Thiamine is given to optimize cellular oxygen utilization and energy consumption, protecting the heart, brain, and immune system. The It administered early, this formula of FDA-approved, sate, inexpensive, and readily available drugs can eliminate the need for ICU beds and mechanical ventilators and return patients to health.

#### DISCLAIMER

This protocol is solely for educational purposes regarding potentially beneficial therapies for COVID-19. Never disregard professional medical advice because of something you have read on our website and releases. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment in regards to any patient. Treatment for an individual patient should rely on the judgement of your physician or other qualified health provider. Always seek their advice with any questions you may have regarding your health or medical condition.

#### CONTACT

FLCCC Alliance	2001 L St NW Suite 500	Physician Contact	Media Relations
www.flccc.net	Washington, DC 20036	support@flccc.net	press@flccc.net



Please check our homepage www.flccc.net regularly for updates of our COVID-19 Protocols! – New medications may be added and/or dose changes to existing medications may be made as further scientific studies emerge!

flccc.net

Dr. Zelenko Covid-19 Treatment Protocol: <a href="https://vladimirzelenkomd.com/treatment-protocol/">https://vladimirzelenkomd.com/treatment-protocol/</a>

Items in	orange are available OTC, others	are prescrip	tion	
Prophylaxis			Treatment	
1000mg, daily	Vitamin C	same	1000mg, 7 days	
5000IU 125mcg, daily	Vitamin D3	double	10000IU 250mcg, 7 days OR 50000IU, 1-2 days	
25mg, daily	Elemental Zinc	double	50mg, 7 days	
	Zinc Ionophore			
500mg, daily OR	Quercetin	double -	500mg, 2x - 7 days OR	
400mg, daily OR	Epigallocatechin-gallate (EGCG)	same -	400mg, 1x - 7 days OR	
200mg, 5 days, 200-400mg weekly OR	Hydroxychloroquine (HCQ)	double -	200mg, 2x - 5-7 days AND/OR	
0.2mg/kg, day 1 & 3, weekly *Example: IVM dosage	lvermectin (IVM)* for 200lb person (90kg) - Prophylaxi	double	0.4-0.5mg/kg, 5-7 days atment 36mg-45mg	
	Antibiotic	0,		
	Azithromycin (Z-PAK)	add	500mg, 1x - 5 days OR	
***	Doxycycline	add	100mg, 2x - 7 days	
	Other Treatment Options		19	
corticosteroid	Dexamethasone 6-12mg 1 time a day for 7 days or			
corticosteroid	Prednisone 20mg twice a day for 7 days, taper as needed			
corticosteroid	Budesonide 1mg/2cc solution via nebulizer twice a day for 7 days			
blood thinners	Blood thinners (i.e. Lovenox, Eliquis, Xarelto, Pradaxa, Aspirin)			
anti-inflammatory	Colchicine 0.6mg 2-3 times a day for 5-7 days			
	Monoclonal antibodies			
	Home IV fluids and oxygen			